You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
AstraZeneca
McKesson
Moodys
Mallinckrodt

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

GLATIRAMER ACETATE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Glatiramer Acetate, and what generic alternatives are available?

Glatiramer Acetate is a drug marketed by Mylan and is included in two NDAs.

The generic ingredient in GLATIRAMER ACETATE is glatiramer acetate. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the glatiramer acetate profile page.

US ANDA Litigation and Generic Entry Outlook for Glatiramer Acetate

A generic version of GLATIRAMER ACETATE was approved as glatiramer acetate by MYLAN on October 3rd, 2017.

  Start Trial

Drug patent expirations by year for GLATIRAMER ACETATE
Drug Prices for GLATIRAMER ACETATE

See drug prices for GLATIRAMER ACETATE

Recent Clinical Trials for GLATIRAMER ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
VU University Medical CenterN/A
Assiut UniversityPhase 1
Mapi Pharma Ltd.Phase 3

See all GLATIRAMER ACETATE clinical trials

Medical Subject Heading (MeSH) Categories for GLATIRAMER ACETATE
Paragraph IV (Patent) Challenges for GLATIRAMER ACETATE
Tradename Dosage Ingredient NDA Submissiondate
COPAXONE FOR SOLUTION;SUBCUTANEOUS glatiramer acetate 020622 2014-02-26
COPAXONE INJECTABLE;SUBCUTANEOUS glatiramer acetate 020622 2014-02-26
COPAXONE INJECTABLE;SUBCUTANEOUS glatiramer acetate 020622 2007-12-27
COPAXONE FOR SOLUTION;SUBCUTANEOUS glatiramer acetate 020622 2007-12-27

US Patents and Regulatory Information for GLATIRAMER ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan GLATIRAMER ACETATE glatiramer acetate INJECTABLE;SUBCUTANEOUS 091646-001 Oct 3, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
Mylan GLATIRAMER ACETATE glatiramer acetate INJECTABLE;SUBCUTANEOUS 206936-001 Oct 3, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
AstraZeneca
McKesson
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.